In our μKO studies, we showed that microglia utilize RIPK2 to promote stroke injury and that deleting the Ripk2 gene specifically in microglia results in decreased infarct size and reduced markers of BBB disruption. The gene discussed is RIPK2; the disease is stroke disorder.